ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

AVCT Avacta Group Plc

49.75
0.75 (1.53%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Avacta Group Plc LSE:AVCT London Ordinary Share GB00BYYW9G87 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.75 1.53% 49.75 49.50 50.00 49.75 47.50 48.75 3,399,639 16:13:35
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 10.06M -39.19M -0.1382 -3.60 141.1M

Avacta Group PLC Avacta to Present at Major European Conference

12/11/2018 7:00am

RNS Non-Regulatory


TIDMAVCT

Avacta Group PLC

12 November 2018

12 November 2018

Avacta Group plc

("Avacta" or "the Group" or "the Company")

Avacta's Chief Scientific Officer to Present Recent Data at Major European Conference

Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and reagents, is pleased to announce that its Chief Scientific Officer, Dr Amrik Basran, will be presenting at the Protein Engineering Society of Europe meeting, which is taking place in Lisbon on 14 November 2018. Dr Basran will be presenting recent data relating to the pre-clinical development of the Group's lead therapeutic programme, a PD-L1/LAG-3 single molecule bispecific.

Dr Basran will focus particularly on the development of novel Affimer(R) bispecific formats that inhibit two immune checkpoints simultaneously. PD-L1 plays a key role in suppressing the immune system, and by blocking this checkpoint protein on tumour cells, it assists the immune system's attack on the cancer. The blocking of LAG-3 on T-cells helps to maintain the immune system attack and reduce T-cell exhaustion.

The Group is developing this single molecule bispecific therapy with a view to entering phase I clinical development in 2020, which will yield first-in-man clinical data for the Affimer(R) platform. Avacta is also building a pipeline of novel immuno-oncology Affimer(R) assets for clinical development and licensing.

- Ends -

For further information from Avacta Group plc, please contact:

 
 Avacta Group plc                           Tel: +44 (0) 844 414 0452 
  Alastair Smith, Chief Executive Officer    www.avacta.com 
  Tony Gardiner, Chief Financial Officer 
 finnCap Ltd                                Tel: +44 (0) 207 220 0500 
  Geoff Nash / Giles Rolls - Nominated       www.finncap.com 
  Adviser 
  Tim Redfern - Corporate Broking 
                                             Tel: +44 (0) 203 705 9318 
  WG Partners                                Tel: +44 (0) 203 705 9317 
  Nigel Birks / Nigel Barnes                 www.wgpartners.co.uk 
  David Wilson / Claes Spang 
 Zyme Communications (Trade and Regional    Tel: +44 (0)7787 502 947 
  Media)                                     katie.odgaard@zymecommunications.com 
  Katie Odgaard 
 
  Yellow Jersey (Financial Media and         Tel: +44 (0)7764 947137 
  IR)                                        Tel: +44 (0)7946 424 651 
  Sarah Hollins                              avacta@yellowjerseypr.com 
  Katie Bairsto 
 

About Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer(R) technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer(R) technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer(R) technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer(R) reagents through licensing to developers of life sciences research tools and diagnostics.

To register for news alerts by email go to www.avacta.com/investor-news-email-alerts

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAFSWFMUFASEIF

(END) Dow Jones Newswires

November 12, 2018 02:00 ET (07:00 GMT)

1 Year Avacta Chart

1 Year Avacta Chart

1 Month Avacta Chart

1 Month Avacta Chart

Your Recent History

Delayed Upgrade Clock